Ibrutinib in relapsed/refractory patients with Waldenström macroglobulinemia: a real-life, retrospective study on behalf of the “RTL” (regional Tuscan lymphoma network)-Reference-Cited by-同舟云学术

Ibrutinib in relapsed/refractory patients with Waldenström macroglobulinemia: a real-life, retrospective study on behalf of the “RTL” (regional Tuscan lymphoma network)

Published:2023-02-03 Issue:4 Volume:102 Page:841-849
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Cencini Emanuele^ORCID,Romano Ilaria,Ghio Francesco,Camerini Chiara,Bertaggia Ilaria,Giachetti Roberta,Mannelli Lara,Pirrotta Maria Teresa,Navei Giulia Lucco,Ciceri Manuel,Cervetti Giulia,Sant’Antonio Emanuela,Simonetti Federico,Birtolo Silvia,Puccini Benedetta,Bocchia Monica,Fabbri Alberto

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00277-023-05113-9.pdf

Reference30 articles.

1. Pratt G, El-Sharkawi D, Kothari J, D’Sa S, Auer R, McCarthy H, Krishna R, Miles O, Kyriakou C, Owen R (2022) Diagnosis and management of Waldenström macroglobulinaemia-a British Society for Haematology guideline. Br J Haematol 197(2):171–187. https://doi.org/10.1111/bjh.18036

2. Kastritis E, Leblond V, Dimopoulos MA, Kimby E, Staber P, Kersten MJ, Tedeschi A, Buske C, Guidelines Committee ESMO (2018) Waldenström’s macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 29(Suppl 4):41–50. https://doi.org/10.1093/annonc/mdy322

3. Gertz MA (2021) Waldenström macroglobulinemia: 2021 update on diagnosis, risk stratification, and management. Am J Hematol 96(2):258–269. https://doi.org/10.1002/ajh.26082

4. Treon SP, Xu L, Yang G, Zhou Y, Liu X, Cao Y, Sheehy P, Manning RJ, Patterson CJ, Tripsas C, Arcaini L, Pinkus GS, Rodig SJ, Sohani AR, Harris NL, Laramie JM, Skifter DA, Lincoln SE, Hunter ZR (2012) MYD88 L265P somatic mutation in Waldenström’s macroglobulinemia. N Engl J Med 367(9):826–833. https://doi.org/10.1056/NEJMoa1200710

5. Treon SP, Cao Y, Xu L, Yang G, Liu X, Hunter ZR (2014) Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia. Blood 123(18):2791–2796. https://doi.org/10.1182/blood-2014-01-550905

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ibrutinib in therapy of Waldenstrom’s macroglobulinemia: literature review and clinical observation;MD-Onco;2023-09-19